Showing 141 - 160 results of 128,850 for search '(( i e decrease ) OR ( 5 ((((fold decrease) OR (mean decrease))) OR (a decrease)) ))', query time: 2.14s Refine Results
  1. 141
  2. 142

    C2GnT1 gene knock-down results in decreased binding of cells to E-selectin. by Catherine A. St. Hill (357388)

    Published 2013
    “…At a shear stress of 0.5 dynes/cm<sup>2</sup>, significantly fewer C2GnT1 shRNA transduced cells accumulated on E-selectin than un-manipulated LS174T cells, *p = 0.04. …”
  3. 143
  4. 144

    Reproductive transition paralleled a significant decrease in LDH5 and LDH1 expressions in nonTg hippocampus. by Fan Ding (302565)

    Published 2013
    “…F. LDH5/LDH1 ratio decreased significantly at 15 months of age. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001, bars represent mean value ± SEM.…”
  5. 145
  6. 146
  7. 147
  8. 148
  9. 149
  10. 150

    At E9.5 Actb<sup>−/−</sup> neural crest cells show a significant decrease of cadherin-11 expression. by Davina Tondeleir (426905)

    Published 2014
    “…<p>(A) Quantification of N-cadherin intensities in Actb<sup>+/+</sup> and Actb<sup>−/−</sup> migratory cells adjacent to the neural tube at E8.5 and E9.5 (left graph, Y-axis: relative intensities) and colocalization of N-cadherin with p75 in migratory cells at E8.5 and E9.5 (right graph, Y-axis: colocalization index on a scale from 0 to 1). …”
  11. 151
  12. 152
  13. 153

    Dexamethasone decreases CRTC1 and CRTC2 nuclear localization. by Jill A. Rahnert (2872766)

    Published 2016
    “…<p>Treatment of L6 myotubes with Dex (100nM, 48hrs) decreased (A) total CRTC1 (p = 0.004 and CRTC2 protein (p = 0.0007). n = 9/treatment from 3 experiments. …”
  14. 154

    Dexamethasone decreases PGC-1α protein expression and transcription. by Jill A. Rahnert (2872766)

    Published 2016
    “…<p>(A) Treatment of L6 myotubes with Dex (100nM, 48hrs) decreased PGC-1α protein expression (p = 0.01). n = 3/treatment from 3 experiments. …”
  15. 155

    VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival. by Aye M. Mon (5714912)

    Published 2018
    “…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10<sup>-5</sup>), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10<sup>-5</sup>), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10<sup>-22</sup>), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10<sup>-71</sup>), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10<sup>-28</sup>), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10<sup>-12</sup>), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10<sup>-10</sup>) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10<sup>-17</sup>). …”
  16. 156
  17. 157
  18. 158
  19. 159
  20. 160